| Name | BioPharma Credit |
|---|---|
| Epic | BPCR |
| Isin | GB00BDGKMY29 |
| Index | UK250 UK350 |
| Industry |
| Latest share price | $0.85 | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | $1,008.83 | Debt ratio | n/a |
| Shares in issue | 1,190.01 | Debt-to-equity ratio | n/a |
| P/E ratio | 8.3 | Assets / equity ratio | n/a |
| Total dividends per share | 7.29p | Price to book value | n/a |
| Dividend yield | 8.3 | ROCE | |
| Dividend cover | 1.44 | EPS growth | |
| Earning per share | 10.11 | 52-week high / low | $0.83 / $0.94 |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| Special | 2024-09-26 | 2024-10-29 | 2.04p |
| 3rd Interim | 2024-09-26 | 2024-10-29 | 1.75¢ |
| 2nd Interim | 2024-07-04 | 2024-07-31 | 1.75¢ |
| 1st Interim | 2024-03-28 | 2024-04-30 | 1.75¢ |
| Special | 2024-02-15 | 2024-03-15 | 1.2079¢ |
| 4th Interim | 2024-02-15 | 2024-03-15 | 1.75¢ |
| Special | 2023-12-07 | 2024-01-05 | 2.00¢ |
| 3rd Interim | 2023-12-07 | 2024-01-05 | 1.75¢ |
| 2nd Interim | 2023-08-17 | 2023-09-15 | 1.75¢ |
| Company name | BioPharma Credit |
|---|---|
| Address | 51 New North Road, Exeter, United Kingdom, EX4 4EP |
| Telephone | +44 (0)1392 477500 |
| Website | http://www.bpcruk.com |
| Director | Position |
|---|---|
| Mr Harry Abraham Hyman | Chairman |
| Ms Sapna Shah | Non-Executive Director |
| Mr Duncan W A Budge | Senior Independent Director |
| Mr Rolf Soderstrom | Independent Non-Executive Director |
| Ms Stephanie Léouzon | Independent Non-Executive Director |
| Mr Colin Bond | Independent Non-Executive Director |
| Assets $ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Reporting date | 31/12/23 | 31/12/22 | 31/12/21 |
| Intangible asssets and goodwill | n/a | n/a | n/a |
| Investments and other non-current assets | |||
| Total non-current assets | |||
| Inventory / work in progress | |||
| Trade and other receivables | |||
| Cash and equivalents | 135.05 | 120.53 | 0.09 |
| Other current assets and asset held for resale | |||
| Total of all assets | 1356.73 | 1364.02 | 1.37 |
| Liabilities $ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Short term liabilities | |||
| Long term liabilities | |||
| Other liabilites / pension etc | |||
| Total of all liabilities | 15.87 | 26.56 | 0.01 |
| Net assets $ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Net assets | 1340.86 | 1337.45 | 1.36 |
| Equity $ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Share capital | |||
| Minority interests | n/a | n/a | n/a |
| Retained earnings | |||
| Share premium account | 607.12 | 607.12 | 0.61 |
| Total equity |
| Income $ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Turnover | 159.68 | 212.22 | 127.63 |
| Operating profit | 132.4 | 176.39 | 108.73 |
| Pre-tax profit | 132.4 | 176.39 | 108.73 |